China News Service, Shanghai, November 6 (Reporter Jiang Yu) The multinational pharmaceutical company Sanofi and Shanghai Pharmaceuticals Holdings Co., Ltd. held a deepening strategic cooperation signing ceremony at the 9th China International Import Expo on the 6th. On the basis of long-term cooperation, the two parties will further leverage their respective advantages in global innovation and local industrial resources, work together to improve the accessibility of medicines, and promote more innovative results to benefit Chinese patients.
From R&D collaboration to innovation accessibility, the cooperative practice at the CIIE is the epitome of Sanofi’s continued integration into China’s pharmaceutical innovation ecosystem. Currently, Sanofi cooperates with more than 900 institutions in China, covering many aspects from early research, clinical development to commercialization.
Schwang, President of Sanofi Greater China, said: "Sanofi has participated in the CIIE for nine consecutive years and has showcased more than 150 innovative drugs, vaccines and R&D pipeline results. We have witnessed the innovative results from the exhibition stand to the clinic, and deeply feel that China's role in the global pharmaceutical innovation process has continued to deepen. As a window for China's high-level opening up, the CIIE has given innovation a broader market and provided longer-term confidence in cooperation."
On the same day, Bayer Health Consumer Products and Xianle Health Technology Co., Ltd. announced the establishment of the "Bayer-Xianle Health Joint Laboratory Evidence-Based Research Platform" at the CIIE, and held a signing and unveiling ceremony to start further cooperation between the two parties in the fields of nutritional and health scientific research and innovation transformation.
According to reports, the joint laboratory takes scientific evidence-based innovation as its core, integrates Bayer's advantages in brand, product and consumer insights, and Xianle Health's capabilities in evidence-based research, R&D verification and innovation transformation to jointly create an innovation empowerment platform that connects scientific discovery, evidence-based verification to commercial implementation.
Li Xiaomeng, head of R&D for Bayer Health Consumer Products China, said: "We will work with Xianle Health to delve deeply into the field of dietary nutrition to help consumers 'choose and eat right'."
Aptiv, a global industrial technology company, signed strategic cooperation agreements with Shanghai Taishizhihang Technology Co., Ltd. and Shanghai Electric Group Co., Ltd. at its CIIE booth on the same day to further expand its business layout in the field of embodied intelligent robots.
Shi Zhihang is an embodied intelligence company that focuses on physical world AI and general robotics technology to promote the application of embodied intelligence in real industrial scenarios. Shanghai Electric is an important force in China's high-end equipment manufacturing, with profound accumulation in the fields of intelligent manufacturing, complete robots, core components and system integration. Hundreds of embodied robots from the two companies will gradually enter Aptiv's front-line production scenarios to jointly carry out robot technology verification and solution optimization, promoting their move from the laboratory to the production line, and from single-point verification to large-scale application.
"Although automobiles and embodied robots have different application scenarios, their technologies have the same origin, the underlying layers are connected, and the industrial chain is common. Aptiv has accumulated mature product technology, system engineering and large-scale mass production experience in the automotive field. We hope to expand these capabilities to emerging fields such as robots to provide support for accelerating the development of robot products, improving reliability and realizing large-scale applications." said Dr. Yang Xiaoming, President of Aptiv China and Asia Pacific.
